keyword
MENU ▼
Read by QxMD icon Read
search

Reduced ejection fraction

keyword
https://www.readbyqxmd.com/read/28448632/correction-right-atrial-volume-by-cardiovascular-magnetic-resonance-predicts-mortality-in-patients-with-heart-failure-with-reduced-ejection-fraction
#1
(no author information available yet)
[This corrects the article DOI: 10.1371/journal.pone.0173245.].
2017: PloS One
https://www.readbyqxmd.com/read/28447583/prevalence-and-clinical-significance-of%C3%A2-diabetes-in-asian-versus-white-patients%C3%A2-with-heart-failure
#2
Ingrid E M Bank, Crystel M Gijsberts, Tiew-Hwa K Teng, Lina Benson, David Sim, Poh Shuan Daniel Yeo, Hean Yee Ong, Fazlur Jaufeerally, Gerard K T Leong, Lieng H Ling, A Mark Richards, Dominique P V de Kleijn, Ulf Dahlström, Lars H Lund, Carolyn S P Lam
OBJECTIVES: The study sought to compare the prevalence, clinical correlates and prognostic impact of diabetes in Southeast Asian versus white patients with heart failure (HF) with preserved or reduced ejection fraction. BACKGROUND: Diabetes mellitus is common in HF and is associated with impaired prognosis. Asia is home to the majority of the world's diabetic population, yet data on the prevalence and clinical significance of diabetes in Asian patients with HF are sparse, and no studies have directly compared Asian and white patients...
January 2017: JACC. Heart Failure
https://www.readbyqxmd.com/read/28447181/sglt-2-inhibition-with-dapagliflozin-reduces-the-activation-of-the-nlrp3-asc-inflammasome-and-attenuates-the-development-of-diabetic-cardiomyopathy-in-mice-with-type-2-diabetes-further-augmentation-of-the-effects-with-saxagliptin-a-dpp4-inhibitor
#3
Yumei Ye, Mandeep Bajaj, Hsiu-Chiung Yang, Jose R Perez-Polo, Yochai Birnbaum
PURPOSE: We assessed whether (1) dapagliflozin (Dapa, an SGLT2-inhibitor) attenuates the deterioration of heart function Nlrp3 and inflammasome activation in diabetic mice. (2) The effects can be augmented with saxagliptin (Saxa), a DDP4-inhibitor. (3) Dapa effect is possibly SGLT2-independent on cardiofibroblasts in vitro. METHODS: Type 2 diabetic (BTBR ob/ob) and wild-type (WT) mice received vehicle, Dapa, or Dapa+Saxa for 8 weeks. Glucose tolerance test and echocardiogram were performed...
April 26, 2017: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/28446734/iron-deficiency-and-anemia-in-heart-failure
#4
Yüksel Çavuşoğlu, Hakan Altay, Mustafa Çetiner, Tolga Sinan Güvenç, Ahmet Temizhan, Dilek Ural, Dilek Yeşilbursa, Nesligül Yıldırım, Mehmet Birhan Yılmaz
Heart failure is an important community health problem. Prevalence and incidence of heart failure have continued to rise over the years. Despite recent advances in heart failure therapy, prognosis is still poor, rehospitalization rate is very high, and quality of life is worse. Co-morbidities in heart failure have negative impact on clinical course of the disease, further impair prognosis, and add difficulties to treatment of clinical picture. Therefore, successful management of co-morbidities is strongly recommended in addition to conventional therapy for heart failure...
March 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28446199/different-determinants-of-exercise-capacity-in-hfpef-compared-to-hfref
#5
Arlind Batalli, Pranvera Ibrahimi, Ibadete Bytyçi, Artan Ahmeti, Edmond Haliti, Shpend Elezi, Michael Y Henein, Gani Bajraktari
BACKGROUND: Quality of life is as important as survival in heart failure (HF) patients. Controversies exist with regards to echocardiographic determinants of exercise capacity in HF, particularly in patients with preserved ejection fraction (HFpEF). The aim of this study was to prospectively examine echocardiographic parameters that correlate and predict functional exercise capacity assessed by 6 min walk test (6-MWT) in patients with HFpEF. METHODS: In 111 HF patients (mean age 63 ± 10 years, 47% female), an echo-Doppler study and a 6-MWT were performed in the same day...
April 26, 2017: Cardiovascular Ultrasound
https://www.readbyqxmd.com/read/28445944/angiotensin-converting-enzyme-2-overexpression-protects-against-doxorubicin-induced-cardiomyopathy-by-multiple-mechanisms-in-rats
#6
Hui Ma, Jing Kong, Yu-Lin Wang, Jun-Long Li, Nai-Hao Hei, Xin-Ran Cao, Jing-Jing Yang, Wen-Jiang Yan, Wen-Jing Liang, Hong-Yan Dai, Bo Dong
Angiotensin-converting enzyme 2 (ACE2) is considered a potential therapeutic target of the renin-angiotensin system (RAS) for the treatment of cardiovascular diseases. We aimed to explore the effects of ACE2 overexpression on doxorubicin-induced cardiomyopathy in rats. Rats were randomly divided into treatment and control groups. The rats of treatment group were injected intraperitoneally with 6 doses of doxorubicin (2.5 mg/kg) within a period of two weeks. Two weeks after the initial injection of doxorubicin, these rats were randomly divided into Mock, Ad-EGFP, Ad-ACE2, and Cilazapril groups...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28444160/echo-doppler-estimation-of-left-ventricular-filling-pressure-results-of-the-multicentre-eacvi-euro-filling-study
#7
Patrizio Lancellotti, Maurizio Galderisi, Thor Edvardsen, Erwan Donal, Georg Goliasch, Nuno Cardim, Julien Magne, Sara Laginha, Andreas Hagendorff, Trine F Haland, Lars Aaberge, Christophe Martinez, Antonio Rapacciuolo, Ciro Santoro, Federica Ilardi, Adriana Postolache, Raluca Dulgheru, Anca D Mateescu, Carmen C Beladan, Dan Deleanu, Stella Marchetta, Vincent Auffret, Ehud Schwammenthal, Gilbert Habib, Bogdan A Popescu
Aims: The present Euro-Filling report aimed at comparing the diagnostic accuracy of the 2009 and 2016 echocardiographic grading algorithms for predicting invasively measured left ventricular filling pressure (LVFP). Method and results: A total of 159 patients who underwent simultaneous evaluation of echo estimates of LVFP and invasive measurements of LV end-diastolic pressure (LVEDP) were enrolled at nine EACVI centres. Thirty-nine (25%) patients had a reduced LV ejection fraction (<50%), 77 (64%) were in NYHA ≥ II, and 85 (53%) had coronary artery disease...
April 22, 2017: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/28441235/noninvasive-iphone-measurement-of-left-ventricular-ejection-fraction-using-intrinsic-frequency-methodology
#8
Niema M Pahlevan, Derek G Rinderknecht, Peyman Tavallali, Marianne Razavi, Thao T Tran, Michael W Fong, Robert A Kloner, Marie Csete, Morteza Gharib
OBJECTIVE: The study is based on previously reported mathematical analysis of arterial waveform that extracts hidden oscillations in the waveform that we called intrinsic frequencies. The goal of this clinical study was to compare the accuracy of left ventricular ejection fraction derived from intrinsic frequencies noninvasively versus left ventricular ejection fraction obtained with cardiac MRI, the most accurate method for left ventricular ejection fraction measurement. DESIGN: After informed consent, in one visit, subjects underwent cardiac MRI examination and noninvasive capture of a carotid waveform using an iPhone camera (The waveform is captured using a custom app that constructs the waveform from skin displacement images during the cardiac cycle...
April 22, 2017: Critical Care Medicine
https://www.readbyqxmd.com/read/28439731/il-10-improves-cardiac-remodeling-after-myocardial-infarction-by-stimulating-m2-macrophage-polarization-and-fibroblast-activation
#9
Mira Jung, Yonggang Ma, Rugmani Padmanabhan Iyer, Kristine Y DeLeon-Pennell, Andriy Yabluchanskiy, Michael R Garrett, Merry L Lindsey
Inflammation resolution is important for scar formation following myocardial infarction (MI) and requires the coordinated actions of macrophages and fibroblasts. In this study, we hypothesized that exogenous interleukin-10 (IL-10), an anti-inflammatory cytokine, promotes post-MI repair through actions on these cardiac cell types. To test this hypothesis, C57BL/6J mice (male, 3- to 6-month old, n = 24/group) were treated with saline or IL-10 (50 μg/kg/day) by osmotic mini-pump infusion starting at day (d) 1 post-MI and sacrificed at d7 post-MI...
May 2017: Basic Research in Cardiology
https://www.readbyqxmd.com/read/28438373/geriatric-nutritional-risk-index-as-a-nutritional-and-survival-risk-assessment-tool-in-stable-outpatients-with-systolic-heart-failure
#10
L Sargento, A Vicente Simões, J Rodrigues, S Longo, N Lousada, R Palma Dos Reis
BACKGROUND AND AIMS: Malnutrition is frequent in heart failure (HF). However, the best tool for evaluating malnutrition in geriatric patients with HF with reduced ejection fraction (HFrEF) is unknown. This study aimed to evaluate the incremental prognostic value of the geriatric nutritional risk index (GNRI) in stable geriatric outpatients with HFrEF compared with a clinical/laboratory prognostic model. METHODS AND RESULTS: A total of 143 outpatients with HFrEF, aged >65 years, a LVEF <40%, and who were stable and on optimal therapy were studied...
February 22, 2017: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/28437711/cardiomyocyte-ca-2-homeostasis-as-a-therapeutic-target-in-heart-failure-with-reduced-and-preserved-ejection-fraction
#11
REVIEW
Deborah Peana, Timothy L Domeier
Heart failure is a highly prevalent syndrome of multiple etiologies and associated comorbidities, and aberrant intracellular Ca(2+) homeostasis is a hallmark finding in heart failure patients. The cyclical changes in Ca(2+) concentration within cardiomyocytes control cycles of cardiac contraction and relaxation, and dysregulation of Ca(2+) handling processes leads to systolic dysfunction, diastolic dysfunction, and adverse remodeling. For this reason, greater understanding of Ca(2+) handling mechanisms in heart failure is critical for selection of appropriate treatment strategies...
April 21, 2017: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/28434933/assessing-the-eligibility-criteria-in-phase-iii-randomized-controlled-trials-of-drug-therapy-in-heart-failure-with-preserved-ejection-fraction-the-critical-play-off-between-a-pure-patient-phenotype-and-the-generalizability-of-trial-findings
#12
Hitesh C Patel, Carl Hayward, Jason Dungu, Sofia Papadopoulou, Abdel Saidmeerasah, Carlo Di Mario, Nesan Shanmugam, Martin R Cowie, Lisa J Anderson
AIMS: To investigate the effect of the different eligibility criteria used by phase III clinical studies in heart failure with preserved ejection fraction (HFpEF) on patient selection, phenotype and survival. METHODS AND RESULTS: We applied the key eligibility criteria of seven phase III HFpEF studies (DIG-Ancillary, CHARM-Preserved, PEP-CHF, I-PRESERVE, J-DHF, TOPCAT and PARAGON-HF [on-going]) to a typical and well-characterised HFpEF population (n=557) seen in modern European cardiological practice...
April 18, 2017: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/28434020/bisoprolol-compared-with-carvedilol-and-metoprolol-succinate-in-the-treatment-of-patients-with-chronic-heart-failure
#13
Hanna Fröhlich, Lorella Torres, Tobias Täger, Dieter Schellberg, Anna Corletto, Syed Kazmi, Kevin Goode, Morten Grundtvig, Torstein Hole, Hugo A Katus, John G F Cleland, Dan Atar, Andrew L Clark, Stefan Agewall, Lutz Frankenstein
AIMS: Beta-blockers are recommended for the treatment of chronic heart failure (CHF). However, it is disputed whether beta-blockers exert a class effect or whether there are differences in efficacy between agents. METHODS AND RESULTS: 6010 out-patients with stable CHF and a reduced left ventricular ejection fraction prescribed either bisoprolol, carvedilol or metoprolol succinate were identified from three registries in Norway, England, and Germany. In three separate matching procedures, patients were individually matched with respect to both dose equivalents and the respective propensity scores for beta-blocker treatment...
April 22, 2017: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/28432646/is-there-a-role-for-ivabradine-in-the-contemporary-management-of-patients-with-chronic-heart-failure-in-academic-and-community-heart-failure-clinics-in-canada
#14
Sherryn Roth, Carlos Fernando, Sadia Azeem, Gordon W Moe
INTRODUCTION: In patients with heart failure (HF) and reduced ejection fraction, increased heart rate (HR) is an independent risk factor for adverse outcomes. In systolic HF treatment with the If inhibitor ivabradine trial (SHIFT), Ivabradine improved survival when added to conventional treatment including β-blockers. However, the extent of benefit in the real world is unclear. We examined the characteristics of patients on guideline-directed therapy and determined who had SHIFT-like characteristics...
April 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28432058/mk5-haplodefficiency-attenuates-hypertrophy-and-preserves-diastolic-function-during-remodeling-induced-by-chronic-pressure-overload-in-the-mouse-heart
#15
Sherin Nawaito, Dharmendra Dingar, Pramod Sahadevan, Bahira Hussein, Fatiha Sahmi, Yanfen Shi, Marc-Antoine Gillis, Matthias Gaestel, Jean-Claude Tardif, Bruce G Allen
MK5 is a protein serine and threonine kinase that is activated by p38 MAPK and the atypical MAPKs ERK3 and ERK4. The physiological function(s) of MK5 remain unknown. Herein we examine the effect of MK5 haplodeficiency on cardiac function and myocardial remodeling. At 12-weeks of age, MK5 haplodeficient mice (MK5(+/-)) were smaller than age-matched wild-type litter mates (MK5(+/+)), with similar diastolic function but reduced systolic function. Transverse aortic constriction (TAC) was employed to induce a chronic pressure overload in twelve-week-old male MK5(+/-) and MK5(+/+) mice...
April 21, 2017: American Journal of Physiology. Heart and Circulatory Physiology
https://www.readbyqxmd.com/read/28431823/sleepiness-and-activity-in-heart-failure-patients-with-reduced-ejection-fraction-and-central-sleep-disordered-breathing
#16
Angela Atalla, Thomas W Carlisle, Anita K Simonds, Martin R Cowie, Mary J Morrell
OBJECTIVE: Patients with heart failure (HF) and sleep disordered breathing (SDB) are typically not sleepy, unlike patients without heart failure. Previous work in HF patients with obstructive SDB suggested that sleepiness was associated with a reduction in daytime activity. The consequences of predominately central SDB on sleepiness in HF are less well understood. The aim of this study was to test the hypothesis that subjective sleepiness is associated with reduced daytime activity in HF patients with central SDB, compared to those without SDB...
January 23, 2017: Sleep Medicine
https://www.readbyqxmd.com/read/28431133/prediction-of-sudden-and-non-sudden-cardiac-death-in-post-infarction-patients-with-reduced-left-ventricular-ejection-fraction-by-periodic-repolarization-dynamics-madit-ii-substudy
#17
Konstantinos D Rizas, Scott McNitt, Wolfgang Hamm, Steffen Massberg, Stefan Kääb, Wojciech Zareba, Jean-Philippe Couderc, Axel Bauer
Aims: To test the value of Periodic Repolarization Dynamics (PRD), a recently validated electrocardiographic marker of sympathetic activity, as a novel approach to predict sudden cardiac death (SCD) and non-sudden cardiac death (N-SCD) and to improve identification of patients that profit from ICD-implantation. Methods and results: We included 856 post-infarction patients with left-ventricular ejection fraction (LVEF) ≤30% of the MADIT-II trial in sinus rhythm...
April 18, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28431059/cardiac-structural-and-functional-profile-of-patients-with-delayed-qrs-transition-zone-and-sudden-cardiac-death
#18
Aapo L Aro, Derek Phan, Carmen Teodorescu, Audrey Uy-Evanado, Kyndaron Reinier, Karen Gunson, Jonathan Jui, Heikki V Huikuri, Sumeet S Chugh
Aims: Delayed QRS transition zone in the precordial leads of the 12-lead electrocardiogram (ECG) has been recently associated with increased risk of sudden cardiac death (SCD), but the underlying mechanisms are unknown. We correlated echocardiographic findings with ECG and clinical characteristics to investigate how alterations in cardiac structure and function contribute to this risk marker. Methods and Results: From the ongoing population-based Oregon Sudden Unexpected Death Study (catchment population ∼1 million), SCD cases with prior ECG available (n = 627) were compared with controls (n = 801)...
April 1, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/28431057/quantitative-analysis-of-pkp2-and-neighbouring-genes-in-a-patient-with-arrhythmogenic-right-ventricular-cardiomyopathy-caused-by-heterozygous-pkp2-deletion
#19
Keiko Sonoda, Seiko Ohno, Sou Otuki, Koichi Kato, Nobue Yagihara, Hiroshi Watanabe, Takeru Makiyama, Tohru Minamino, Minoru Horie
Aims: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease mainly caused by desmosome gene mutations. The genetic culprit, however, remains elusive in ∼50% of ARVC patients. One of the reasons for missing genetic abnormalities is the difficulty in detecting large deletions/duplications, which are called as copy number variation (CNV) by the Sanger sequencing method. This study aimed to identify CNVs in PKP2 and a part of other desmosome genes in ARVC patients. Methods and Results: The study cohort consisted of 71 ARVC probands who were diagnosed as definite or borderline cases based on 2010 Task Force Criteria...
April 1, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/28431003/intracoronary-autologous-bone-marrow-cell-transfer-after-myocardial-infarction-the-boost-2-randomised-placebo-controlled-clinical-trial
#20
Kai C Wollert, Gerd P Meyer, Jochen Müller-Ehmsen, Carsten Tschöpe, Vernon Bonarjee, Alf Inge Larsen, Andreas E May, Klaus Empen, Emmanuel Chorianopoulos, Ulrich Tebbe, Johannes Waltenberger, Heiko Mahrholdt, Benedikta Ritter, Jens Pirr, Dieter Fischer, Mortimer Korf-Klingebiel, Lubomir Arseniev, Hans-Gert Heuft, Jan E Brinchmann, Diethelm Messinger, Bernd Hertenstein, Arnold Ganser, Hugo A Katus, Stephan B Felix, Meinrad P Gawaz, Kenneth Dickstein, Heinz-Peter Schultheiss, Dennis Ladage, Simon Greulich, Johann Bauersachs
Aims: Intracoronary infusion of autologous nucleated bone marrow cells (BMCs) enhanced the recovery of left ventricular ejection fraction (LVEF) after ST-segment elevation myocardial infarction (STEMI) in the randomised-controlled, open-label BOOST trial. We reassessed the therapeutic potential of nucleated BMCs in the randomised placebo-controlled, double-blind BOOST-2 trial conducted in 10 centres in Germany and Norway. Methods and results: Using a multiple arm design, we investigated the dose-response relationship and explored whether γ-irradiation which eliminates the clonogenic potential of stem and progenitor cells has an impact on BMC efficacy...
April 19, 2017: European Heart Journal
keyword
keyword
121015
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"